DataSheet1_Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer.docx by Weina Xu (558990)

“…PTPRD-AS1 knockdown decreased the proliferation, cloning, and migration of CAOV3 cells.…”

Data Sheet 1_Influence of age-adjusted shock index trajectories on 30-day mortality for critical patients with septic shock.zip by Suru Yue (12194255)

“…KM curve revealed significantly higher 30-day mortality in Class 2 (32.1%) and Class 3 (38.7%) than Class 1 (12.3%) (P < 0.001). …”

Data Sheet 1_Comprehensive metagenomic and lipidomic analysis showed that baicalin could improve depressive behaviour in atherosclerotic mice by inhibiting nerve cell ferroptosis.z... by Peng Ren (337555)

“…Metabolic pathway enrichment analysis showed that differential lipid PEs were significantly enriched in the iron death pathway, and our further in vitro cellular experiments showed that baicalin could inhibit Erastin-induced Ferroptosis in the hippocampal neuronal cell line HT-22 by promoting the expression of SLC7A11, GSH, and GPX4, inhibiting the expression of ACSL4, and decreasing the cellular ROS.…”

Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial by Trupti Nagendra Prasad (17266455)

“…Micro finite element analysis-derived strength parameters were unchanged, except for modest increase in tibial stiffness with denosumab. BTMs decreased with anti-resorptives, increased with teriparatide and showed an anabolic window by 6 weeks.…”

Figure 6 from Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes by Laura Kuett (20493991)

“…Circles display significantly enriched (red) or decreased (blue; FDR < 0.05; multiple testing correction with the Benjamin–Hochberg method) results, with size indicating the log-transformed fold change.  …”

Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization by Yu-Xuan Yao (21338594)

“…</p> <p>After meta-analyses of both discovery and validation cohorts, genetically proxied GLP1R agonist was found to significantly associated with a decreased risk of diabetic nephropathy (OR = 0.72, 95%CI = 0.54–0.97, <i>p</i> = 0.031) and IgA nephropathy (OR = 0.58, 95%CI = 0.36–0.94, <i>p</i> = 0.027). …”

Additional file 2 of Whole genome sequencing of the pulmonary microbiome in interstitial lung disease subtypes by Kristel S. Knudsen (10535406)

“…Every red dot on the plot represents differentially abundant species with increased significance noted towards the top of the plot. Grey dot: not significant…”

Elevated serum sFlt-1 at 18–20 weeks in advanced maternal age: a key difference from younger pregnancies by Kazunari Nemoto (22495831)

“…In non-AMA pregnancies, serum sFlt-1 levels tended to be lower in PE cases compared to normotensive (NT) cases. Conversely, in AMA pregnancies, PE cases showed significantly higher serum sFlt-1 levels and sFlt-1/PlGF ratios than NT cases. …”

Table 1_Unpacking the cost implications of diagnosis-related groups reform for lumbar disc herniation patients in Chinese medicine: a closer look at evidence from China.xls by Meng-en Chen (22274533)

“…Objectives<p>Lumbar disc herniation (LDH) presents a significant economic burden globally, worsening in China due to an aging population. …”

Table 1_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.xlsx by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 2_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Data Sheet 1_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.pdf by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 1_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 3_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 5_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Image 4_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.jpeg by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Table 2_Improvements in cancer survival in Hungary: a nationwide epidemiology study between 2011–2019 based on a health insurance fund database.xlsx by Zoltán Kiss (5570003)

“…Age-standardized 5-year net survival rates showed significant improvements from 2011-12 till 2017-19 periods for colorectal cancer from 55.08% to 59.78% (4.70%), lung cancer from 20.10% to 23.55% (3.45%), liver cancer from 11.21% to 16.97% (5.76%) and melanoma from 90.06% to 93.80% (3.73%), while clinically relevant, but not significant improvements for breast cancer from 85.03% to 86.84% (1.81%), prostate cancer from 88.13% to 89.76% (1.63%) and thyroid cancer from 87.23% to 92.36% (5.12%). …”

Table 1_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.docx by Paolo Romania (399007)

“…</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Image 3_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.jpg by Paolo Romania (399007)

“…</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Image 1_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.jpg by Paolo Romania (399007)

“…</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”